Related Experiment Video
Updated: Jun 21, 2026
08:14
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
Recent patents on PCSK9: a new target for treating hypercholesterolemia
Hai Li1, Haixia Li, Nick Ziegler
1Department of VeteransAffairs, Palo Alto Health Care System (154P), Palo Alto, CA 94304, USA. haili_65@yahoo.com
Recent Patents on DNA & Gene Sequences
|July 16, 2009
Summary
Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low-density lipoprotein cholesterol (LDL-c). Inhibiting PCSK9 offers a promising strategy for reducing LDL-c levels and managing hypercholesterolemia.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) is crucial in regulating plasma low-density lipoprotein cholesterol (LDL-c).
- PCSK9 downregulates the low-density lipoprotein receptor (LDLR) in the liver, impacting LDL-c levels.
- Gain-of-function mutations in PCSK9 cause hypercholesterolemia, while loss-of-function mutations lead to hypocholesterolemia.
Purpose of the Study:
- To review current knowledge on PCSK9.
- To summarize recent patents on PCSK9 inhibition strategies for reducing plasma LDL-c.
Main Methods:
- Review of scientific literature and patent applications.
- Analysis of methods targeting PCSK9 expression or activity.
Main Results:
- PCSK9 inhibition is a viable therapeutic approach for lowering LDL-c.
- Various patented methods, including antisense oligonucleotides, siRNAs, antibodies, and small molecules, aim to reduce PCSK9 expression.
Conclusions:
- PCSK9 is a significant therapeutic target for managing hypercholesterolemia.
- Emerging patented technologies offer effective strategies for PCSK9 inhibition and LDL-c reduction.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...